Loading
Extracellular Vesicles in Disease · Journal article
International Journal of Current Science Research and Review · August 10, 2026
A consensus or society position rather than new primary data.
This is a narrative synthesis of exosome science and technology, not a primary clinical trial or meta-analysis. It characterizes exosomes as nano-vehicles with potential in cancer detection and therapy, highlights emerging isolation methods (microfluidics, spectroscopy) and gene-editing applications (CRISPR-Cas), and identifies standardization as a remaining challenge. The evidence base is curated from recent literature but no new empirical results are presented.
Systematic narrative review. Published literature on exosomes and cancer; no specific patient or trial population enrolled.. Intervention: Exosome isolation methods (microfluidics, spectroscopy) and exosome-based cancer detection and treatment approaches, including CRISPR-Cas gene therapy combinations.. Compared with: Synthetic nanoparticles; conventional cancer therapies (implicit, not explicitly compared)..
Exosomes are nano-sized (30–150 nm) extracellular vehicles released via endosomal route and function as intercellular message carriers involved in cancer metastasis Exosome nano-size and biocompatibility confer advantages over synthetic nanoparticles for crossing the blood-brain barrier Microfluidics-based isolation has significantly reduced isolation time compared to conventional methods
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review synthesizes the state of exosome science for oncology professionals but does not provide evidence from controlled trials to support a change in clinical practice. It is useful as a current appraisal of the field and emerging technologies, particularly microfluidics and CRISPR-exosome conjugates, but implementation decisions should await controlled clinical data.
A systematic narrative review synthesizing current knowledge on exosome biology, isolation methods, and cancer applications; provides expert appraisal of emerging technologies but does not report original clinical trial data or hard endpoints.
As stated by the source record.
Quoted from the source exactly as published.
This review synthesizes the state of exosome science for oncology professionals but does not provide evidence from controlled trials to support a change in clinical practice. It is useful as a current appraisal of the field and emerging technologies, particularly microfluidics and CRISPR-exosome conjugates, but implementation decisions should await controlled clinical data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Exosomes are a subset of nano-sized (30–150 nm) extracellular vehicles (EVs) released by cells through the endosomal route, you know like they get made inside and then pushed out. Objective: The primary objective of this scientific review is to give a broad and current appraisal of the intricate biological layout of exosomes, plus modern isolation technologies (for instance microfluidics and spectroscopy), and finally their clinical meaning for cancer detection and treatment. Methods: This article is arranged following systematic review logic based on credible scientific sources from the last decade 2015–2025. Data collection involved international databases, including PubMed, Scopus and Web of Science. The analysis looks at how exosome biogenesis connects with drug delivery systems (DDS), and how that whole interplay affects the tumor microenvironment, using both qualitative and quantitative comparative approaches. The guidelines from the International Society for Extracellular Vesicles (ISEV) were used as a kind of standard for study rigor. Key Findings: A growing body of research suggests that exosomes work as important intercellular message carriers, meaning they are deeply involved in cancer metastasis. Their nano-sized form, the potential to move across the blood-brain barrier (BBB), and their inherent biocompatibility make them a stronger, more natural alternative in comparison with synthetic nanoparticles. Innovative methods such as microfluidics have cut the isolation time a lot, and pairing exosomes with the CRISPR-Cas system has basically opened new directions for gene therapy. In the end, the review also tackles difficulties in standardization and large-scale production, while stressing that exosome engineering is likely the upcoming step change for precision cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.